Arena Pharmaceuticals (ARNA) Rough Share Price Target if Approved

July 30th, 2010 by admin Leave a reply »

Arena Pharmaceuticals (ARNA) Rough Share Price Target if Approved

Zacks Premium FULL ACCESS Membership – 30-day free trial

I have gotten a lot of questions about a target price for Arena or the market share for their drug Lorcaserin if it gets approved. I’ll be honest, I haven’t done a lot of due diligence into the pricing that Arena was looking to put on the drug, but previously I had done an analysis on Vivus for what kind of revenues that company might be expecting.

So I have decided to put out a very rough estimate of what I think the share price could hit if Lorcaserin gets a positive approval vote. Before you read any further though, I would like to mention that I will be putting out an in depth article on pricing in a couple of months, but since Arena shares have been inching up over the last couple of weeks I have decided to release a preliminary ROUGH estimate of market share and share price.
Zecco.com

cont’d on next page

Advertisement

3 comments

  1. Marian says:

    Hi Geoff, I’m your fan.. Can you tell me when is the date of Arena to make the votation of FDA Pannel, and when they will put out the brieffings documents.

    Thanks in advance

    Greetings from Rome!

    Marian

  2. Leo Threefoot says:

    Gek, your price analysis on ARNA was, I’m sorry to say, not helpful. The Esai collaboration has changed the whole picture. Please try again. Thanks

  3. admin says:

    Ok,

    Did you read the article? I suggest you reread the first and second page
    where I explicity stated this.

    Best,

    Geoff

Leave a Reply